The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ analysis
CD8-Positive T-Lymphocytes
/ immunology
Chemoradiotherapy, Adjuvant
Disease-Free Survival
Female
Humans
Immunohistochemistry
Indoleamine-Pyrrole 2,3,-Dioxygenase
/ analysis
Lymphatic Metastasis
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Predictive Value of Tests
Proctectomy
Rectal Neoplasms
/ immunology
Retrospective Studies
Risk Factors
Time Factors
Tumor Microenvironment
Adjuvant treatment strategies
Immune profile
Neoadjuvant therapy
Precision oncology
Rectal cancer
Survival
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
accepted:
20
11
2019
pubmed:
13
12
2019
medline:
18
11
2020
entrez:
13
12
2019
Statut:
ppublish
Résumé
The local immune contexture in patients with locally advanced rectal cancer (LARC) has important prognostic value after neoadjuvant chemoradiation and surgical resection. In this study, we examined the prognostic role of Indoleamine-2,3-Dioxygenase (IDO1) and infiltrating cytotoxic T lymphocytes (CD8+) according to the nodal stage of LARC patients. Expression of IDO1 and CD8 was evaluated through immunohistochemistry in 106 archival tumour tissue samples from patients following neoadjuvant chemoradiation and radical resection. The average infiltration of IDO1+ and CD8+ cells was calculated and expressed as total scores as previously described. Kaplan-Meier curves were used to describe overall and disease-free survival. In nodal-positive tumours (N+), IDO-positivity was associated with a reduced disease-free survival (DFS) (p = 0.063) and CD8-positivity with an impaired OS (p = 0.024). Patients with a N+ LARC and a high total IDO1 score showed a clear advantage regarding five-year disease-free survival rates compared with patients with a low total IDO1 score (N+ 5y-DFS IDO1 high: 66.7% vs IDO low: 19%). We also detected better 5-years-OS rates in N+ LARC with a high total CD8 score (N+ 5y-OS CD8 high: 83.3% vs CD8 low: 32.3%). These survival benefits were not evident in patients with N-tumours. Analysis of the local CD8 and IDO1 expression influences prognosis in nodal-positive LARC patients after multimodal therapy and may be a helpful tool in specifying individual adjuvant treatment strategies according to different immune profiles.
Identifiants
pubmed: 31828368
doi: 10.1007/s00384-019-03466-0
pii: 10.1007/s00384-019-03466-0
doi:
Substances chimiques
Biomarkers, Tumor
0
IDO1 protein, human
0
Indoleamine-Pyrrole 2,3,-Dioxygenase
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
365-370Références
Nat Rev Clin Oncol. 2011 Oct 18;9(2):119-23
pubmed: 22009076
Oncoimmunology. 2014 Dec 15;3(10):e957994
pubmed: 25941578
Cancer Treat Rev. 2019 May;75:1-11
pubmed: 30849607
Lancet Oncol. 2017 Jun;18(6):e354-e363
pubmed: 28593861
Lancet Oncol. 2015 Feb;16(2):200-7
pubmed: 25589192
Trends Cancer. 2018 Jan;4(1):38-58
pubmed: 29413421
PLoS One. 2009 Sep 07;4(9):e6910
pubmed: 19738905
Oncoimmunology. 2015 Feb 03;4(1):e983770
pubmed: 25949864
Lancet Oncol. 2017 Jul;18(7):849-851
pubmed: 28677562
J Clin Oncol. 2011 Feb 20;29(6):610-8
pubmed: 21245428
Nat Rev Cancer. 2006 Aug;6(8):613-25
pubmed: 16862192
Cancer Immunol Immunother. 2019 Apr;68(4):563-575
pubmed: 30671614
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Blood. 2011 Feb 17;117(7):2200-10
pubmed: 21079151
Lancet. 1986 Jun 28;1(8496):1479-82
pubmed: 2425199
Z Gastroenterol. 2017 Dec;55(12):1344-1498
pubmed: 29212104
Clin Cancer Res. 2014 Jan 1;20(1):221-32
pubmed: 24218513
Lancet Oncol. 2014 Dec;15(13):1481-1492
pubmed: 25456367